Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin

Autor:	Shui-Yi Tung, Chi-Ching Chen, Kuo-Liang Wei, Chien-Heng Shen, Huang-Wei Xu, Sheng-Nan Lu, Chih-Wei Yen, Yi-Hsing Chen, Chao-Hung Hung, Te-Sheng Chang, Wei-Ming Chen
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Hemolytic anemia Male medicine.medical_specialty Sofosbuvir Genotype Sustained Virologic Response Anemia Hepatitis C virus Taiwan Hepacivirus medicine.disease_cause Single Center Gastroenterology Antiviral Agents 03 medical and health sciences chemistry.chemical_compound Hemoglobins 0302 clinical medicine Risk Factors Internal medicine Ribavirin Medicine Humans Aged Retrospective Studies Aged 80 and over lcsh:R5-920 business.industry Incidence General Medicine Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Logistic Models chemistry 030220 oncology & carcinogenesis Multivariate Analysis 030211 gastroenterology & hepatology Drug Therapy Combination Female business lcsh:Medicine (General) medicine.drug Kidney disease
Zdroj:	Journal of the Formosan Medical Association, Vol 119, Iss 1, Pp 532-537 (2020)
ISSN:	0929-6646
Popis:	Background/Purpose: The major dose-limiting toxicity of ribavirin is hemolytic anemia. We investigated the incidence, risk factors and impact on virological response of anemia in chronic hepatitis C genotype 2 patients receiving sofosbuvir plus ribavirin therapy. Methods: This was a retrospective real-world analysis of a single center including 293 chronic hepatitis C genotype 2 patients treated with sofosbuvir plus ribavirin for 12 weeks. Severe anemia was defined as hemoglobin concentration
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9220382bb767aee5e611b1642372217e http://www.sciencedirect.com/science/article/pii/S0929664619304139 Zobrazit plný text záznamu